GlassScriptPhysician profile
Christopher Anthony Ross
NPI 1114704145
$2,467.37
in general payments reported to CMS, 2019-2025
18 companies · $779 in 2025
The $779 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $133 · 2024: $1,556 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,059.34 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $391.18 | 2024-2025 | Biktarvy |
| Abbvie INC. | $185.97 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $151.57 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.20 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $105.11 | 2024-2025 | Airsupra |
| Bausch Health US, LLC | $92.48 | 2023-2025 | Aplenzin |
| Theratechnologies INC. | $63.65 | 2024-2025 | Egrifta, Trogarzo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.90 | 2024 | Caplyta |
| Novo Nordisk INC | $39.63 | 2023-2024 | |
| Lilly USA, LLC | $38.20 | 2023-2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $37.56 | 2024 | Spravato |
| Exact Sciences Corporation | $28.89 | 2025 | The Cologuard Plus Collection Kit |
| Indivior INC. | $26.15 | 2025 | Sublocade |
| Mannkind Corporation | $22.26 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.52 | 2025 | Auvelity |
| Amgen INC. | $21.32 | 2024 | Otezla, Repatha |
| Pfizer INC. | $19.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.